Copyright
©The Author(s) 2016.
World J Gastroenterol. Mar 21, 2016; 22(11): 3165-3174
Published online Mar 21, 2016. doi: 10.3748/wjg.v22.i11.3165
Published online Mar 21, 2016. doi: 10.3748/wjg.v22.i11.3165
Table 1 Epidemiological and clinical profiles of patients included in the transversal study n (%)
HBV | HBV + HIV | HBV + HDV | HBV + HDV + HIV | |
(n = 27) | (n = 22) | (n = 31) | (n = 37) | |
Age (yr)1 | 38.54 ± 12.22 | 47.33 ± 8.50 | 41.15 ± 9.33 | 42.32 ± 7.76 |
Gender (M/F) | 21/6 | 12/10 | 22/9 | 17/20 |
Caucasian | 18 (67) | 20 (91) | 27 (87) | 33 (89) |
Subsaharian | 9 (33) | 2 (9) | 4 (13) | 4 (11) |
ALT (IU/mL)1 | 66.58 ± 76.03c | 70.67 ± 18.58 | 112.92 ± 84.39d | 90.40 ± 21.92 |
AST (IU/mL)1 | 42.65 ± 27.76 | 32.67 ± 19.40 | 89.77 ± 62.43 | 38.33 ± 20.12 |
Anti-HCV | 4 (15) | 2 (9) | 2 (6) | 3 (8) |
Anti-HBe | 23 (85) | 17 (77) | 29 (93) | 31 (84) |
HBeAg | 4 (15) | 5 (23) | 2 (7) | 6 (16) |
HBV genotype-A | 17 (63) | 12 (54) | 12 (42) | 16 (43) |
HBV genotype-D | 10 (37) | 10 (46) | 13 (42) | 20 (54) |
HBV genotype-E | 0 | 0 | 4 (9) | 1 (3) |
HBV-DNA (Log10 IU/mL)2 | 3.90 (3.15-5.85)e | 6.97 (5.58-7.25)f | 1.58 (1.00-2.43)g | 2.80 (1.00-7.02) |
HBsAg (Log10 IU/mL)2 | 4.00 (3.81-4.22)h | 5.46 (4.15-5.61)i | 3.83 (3.59-4.39)j | 3.83 (3.24-4.38)k |
HDV-RNA (Log10 copies/mL)2 | NA | NA | 5.20 (4.37-5.74) | 6.89 (4.41-7.73) |
Table 2 Epidemiological and clinical profiles of patients
Age1 | Gender | Precedence | Mode of | Duration of | HBV Genotype2 | Previous | Time without Treatment3 (mo) | Follow-up (mo) | Sampling | |
transmission | infection (yr) | treatment | ||||||||
Pat #1 | 43 | Male | Western Europe | Horizontal | 20 | Undetermined | IFN | 84 | 74 | 8 |
Pat #2 | 30 | Male | Equatorial Ginnea | Unknown | Unknown | A | No | 5 | 4 | |
Pat #3 | 41 | Male | Equatorial Ginnea | Unknown | Unknown | E | No | 2 | 3 | |
Pat #4 | 43 | Male | Eastern Europe | Unknown | Unknown | A | No | 5 | 3 | |
Pat #5 | 45 | Male | Western Europe | IVD | Unknown | A | No | 4 | 4 | |
Pat #6 | 38 | Female | Western Europe | Horizontal | 20 | D | IFN | 36 | 94 | 10 |
Pat #7 | 35 | Female | Western Europe | Horizontal | 25 | E | IFN | 60 | 89 | 13 |
Pat #8 | 55 | Female | Western Europe | Unknown | Unknown | D | No | 17 | 3 | |
Pat #9 | 37 | Male | Equatorial Ginnea | IVD | 22 | A | IFN/ADV | 8 | 77 | 12 |
Pat #10 | 31 | Female | Western Europe | Horizontal | 20 | D | IFN | 12 | 78 | 12 |
Pat #11 | 46 | Male | Western Europe | IVD | 25 | A | No | 53 | 4 | |
Pat #12 | 42 | Male | Western Europe | Unknown | 26 | D | No | 93 | 13 | |
Pat #13 | 45 | Male | Western Europe | Unknown | Unknown | A | No | 42 | 3 | |
Pat #14 | 39 | Male | Western Europe | IVD | 20 | D | No | 41 | 6 | |
Pat #15 | 53 | Male | Western Europe | IVD | 25 | D | No | 89 | 14 | |
Pat #16 | 38 | Female | Equatorial Ginnea | Unknown | Unknown | E | No | 9 | 5 |
Table 3 Hepatitis B virus serological profile of patients
Serum HBV-DNA | HBsAg | ||||||
Genotype1 | Anti-HBe | Status2 | Log10 (IU/mL) (range) | VC | Log10 (IU/mL) (range) | VC | |
Pat #1 | Und | Positive | Negative | NA | NA | 4.40 ± 0.13 (4.20-4.48) | 0.03 |
Pat #2 | A | Positive | Negative | NA | NA | 4.60 ± 0.09 (4.56-4.66) | 0.02 |
Pat #3 | E | Positive | Positive | 2.80 ± 0.29 (2.60-3.01) | 0.10 | 4.46 ± 0.10 (4.39-4.53) | 0.02 |
Pat #4 | A | Positive | Positive | 1.75 ± 1.20 (1.30-2.95) | 0.69 | 3.53 ± 0.14 (3.44-3.63) | 0.04 |
Pat #5 | A | Positive | Positive | 3.25 ± 1.30 (2.13-4.35) | 0.40 | 4.87 ± 0.06 (4.86-4.93) | 0.01 |
Pat #6 | D | Positive | Fluctuating | 2.32 ± 0.70 (1.00-3.42) | 0.30 | 4.52 ± 0.27 (4.01-4.78) | 0.06 |
Pat #7 | E | Positive | Fluctuating | 1.36 ± 0.45 (1.00-2.48) | 0.33 | 3.94 ± 0.10 (3.80-4.12) | 0.03 |
Pat #8 | D | Positive | Fluctuating | 1.65 ± 0.92 (1.00-2.30) | 0.56 | 4.64 ± 0.07 (4.59-4.69) | 0.02 |
Pat #9 | A | Positive | Fluctuating | 1.62 ± 0.88 (1.00-2.48) | 0.54 | 4.17 ± 0.68 (3.68-4.64) | 0.16 |
Pat #10 | D | Positive | Positive | 3.17 ± 0.56 (2.22-4.08) | 0.18 | 3.99 ± 0.19 (3.64-4.13) | 0.05 |
Pat #11 | A | Positive | Negative | NA | NA | 4.55 ± 0.07 (4.48-4.63) | 0.02 |
Pat #12 | D | Negative | Fluctuating | 3.22 ± 1.40 (1.00-4.99) | 0.43 | 4.45 ± 0.09 (4.30-4.58) | 0.02 |
Pat #13 | A | Positive | Negative | NA | NA | 3.85 ± 0.17 (3.73-3.97) | 0.04 |
Pat #14 | D | Positive | Fluctuating | 2.11 ± 0.73 (1.00-2.93) | 0.35 | 3.75 ± 0.10 (3.68-3.82) | 0.03 |
Pat #15 | D | Positive | Positive | 2.76 ± 0.95 (1.97-4.76) | 0.34 | 3.55 ± 0.20 (3.20-3.73) | 0.06 |
Pat #16 | E | Positive | Positive | 2.36 ± 0.10 (2.30-2.48) | 0.04 | 4.28 ± 0.10 (4.21-4.35) | 0.02 |
Table 4 Hepatitis delta virus serological profiles of patients
HDV markers | HCV markers | ||||||
Serum HDV-RNA | Serum HCV-RNA | ||||||
Genotype | Anti-HD IgM | Status1 | Log10 (copies/mL) (range) | VC | Anti-HCV | HCV-RNA | |
Pat #1 | Und | Negative | Positive | 5.90 ± 0.31 (5.53-6.11) | 0.05 | Negative | NA |
Pat #2 | A | Negative | Positive | 5.69 ± 0.05 (5.64-5.72) | 0.01 | Negative | NA |
Pat #3 | E | Negative | Positive | 5.11 ± 0.12 (5.02-5.20) | 0.02 | Negative | NA |
Pat #4 | A | Negative | Positive | 4.38 ± 1.64 (2.60-5.84) | 0.37 | Negative | NA |
Pat #5 | A | Negative | Positive | 6.47 ± 0.64 (5.70-7.18) | 0.10 | Negative | NA |
Pat #6 | D | Positive | Positive | 4.55 ± 2.26 (1.08-5.75) | 0.50 | Negative | NA |
Pat #7 | E | Positive | Positive | 4.01 ± 0.31 (3.57-4.43) | 0.08 | Negative | NA |
Pat #8 | D | Positive | Positive | 4.13 ± 0.35 (3.89-4.38) | 0.08 | Negative | NA |
Pat #9 | A | Positive | Fluctuating | 2.14 ± 0.99 (1.00-3.31) | 0.46 | Negative | NA |
Pat #10 | D | Positive | Fluctuating | 4.07 ± 1.72 (1.00-5.07) | 0.42 | Negative | NA |
Pat #11 | A | Negative | Positive | 5.47 ± 1.33 (4.53-5.47) | 0.24 | Negative | NA |
Pat #12 | D | Positive | Positive | 4.76 ± 1.46 (1.70-6.22) | 0.31 | Negative | NA |
Pat #13 | A | Positive | Positive | 4.53 ± 0.16 (4.41-4.64) | 0.04 | Negative | NA |
Pat #14 | D | Negative | Fluctuating | 3.08 ± 2.95 (1.00-5.17) | 0.96 | Positive | Negative |
Pat #15 | D | Negative | Negative | NA | NA | Positive | Negative |
Pat #16 | E | Positive | Positive | 6.26 ± 0.74 (5.74-6.78) | 0.12 | Negative | NA |
- Citation: Madejón A, Romero M, Hernández &, García-Sánchez A, Sánchez-Carrillo M, Olveira A, García-Samaniego J. Hepatitis B and D viruses replication interference: Influence of hepatitis B genotype. World J Gastroenterol 2016; 22(11): 3165-3174
- URL: https://www.wjgnet.com/1007-9327/full/v22/i11/3165.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i11.3165